ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Grant

Date/time Interval

  • June 1, 2015 - May 31, 2018

    • Awarded By

    Total Award Amount

  • 23222.00

    • Direct Costs

  • 18431.00

    • Sponsor Award Id

    • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Wayne Liang   Investigator